ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v10i4.770ppharm-209Research ArticleДИСКУССИОННЫЕ ВОПРОСЫ ФАРМАКОТЕРАПИИDEBATABLE ISSUES OF PHARMACOTHERAPYОПЫТ ПРИМЕНЕНИЯ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К TNF α — АДАЛИМУМАБА — У РЕБЕНКА С ЮВЕНИЛЬНЫМ ИДИОПАТИЧЕСКИМ АРТРИТОМEXPERIENCE OF APPLYING MONOCLONAL ANTIBODIES TO TNF α — ADALIMUMAB — IN A CHILD WITH JUVENILE IDIOPATHIC ARTHRITISАлексееваЕ. И.AlexeevaE. I.

доктор медицинских наук, профессор, заведующая ревматологическим отделением Научного центраздоровья детей РАМН

PhD, Professor, head of the rheumatology department at the Scientific Center of Children’s Health

alekatya@ya.ruИсаеваК. Б.IsaevaK. B.ДенисоваР. В.DenisovaR. V.СлепцоваТ. В.SleptsovaT. V.ВалиеваС. И.ValiyevaS. I.БзароваТ. М.BzarovaT. M.МитенкоЕ. В.MitenkoE. V.ЧомахидзеА. М.ChomakhidzeA. M.Научный центр здоровья детей РАМН, Москва Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Center of Children’s Health, Moscow The First Sechenov Moscow State Medical UniversityRussian FederationНаучный центр здоровья детей РАМН, Москва, Российская ФедерацияРоссияScientific Center of Children’s Health, Moscow, Russian FederationRussian Federation201314082013104Педиатрическая фармакология149153Copyright © Алексеева Е.И., Исаева К.Б., Денисова Р.В., Слепцова Т.В., Валиева С.И., Бзарова Т.М., Митенко Е.В., Чомахидзе А.М., 20132013Алексеева Е.И., Исаева К.Б., Денисова Р.В., Слепцова Т.В., Валиева С.И., Бзарова Т.М., Митенко Е.В., Чомахидзе А.М.Alexeeva E.I., Isaeva K.B., Denisova R.V., Sleptsova T.V., Valiyeva S.I., Bzarova T.M., Mitenko E.V., Chomakhidze A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/209

The article offers successful application of a preparation of human monoclonal antibodies to tumor necrosis factor (TNF) α – adalimumab – in the setting of a severe course of juvenile idiopathic arthritis characterized by inefficiency of the standard antirheumatic therapy and secondary resistance to chimeric antibodies to TNF α. Adalimumab treatment secured overcoming of the secondary infliximab inefficiency, rapid disease activity decrease, peripheral joints’ function recovery and the patient’s functional activity increase in a short space of time. The drug averted the patient’s steadily progressing incapacitation and induced the clinical-laboratory disease remission development.

детиювенильный идиопатический артритадалимумаблечениеchildrenjuvenile idiopathic arthritisadalimumabtreatmentReferencesFurst D. E., Schiff M. H., Fleischmann R. M., Strand V., Birbara C. A., Сompagnone D. et al. Adalimumab, a fully human anti tumor necrosis factor _ monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003; 30: 2563–2571.Furst D. E., Schiff M. H., Fleischmann R. M., Strand V., Birbara C. A., Сompagnone D. et al. Adalimumab, a fully human antitumor necrosis factor _ monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 2003; 30: 2563–2571.Weinblatt M. E., Keystone E. C., Furst D. E., Moreland L. W., Weisman M. H., Birbara C. A. et al. Adalimumab, a fully human antitumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate the ARMADA trial [published erratum appears in Arthritis Rheum2003,48 855]. Arthritis Rheum. 2003; 48: 35–45.Weinblatt M. E., Keystone E. C., Furst D. E., Moreland L. W., Weisman M. H., Birbara C. A. et al. Adalimumab, a fully human antitumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate the ARMADA trial [published erratum appears in Arthritis Rheum 2003,48 855]. Arthritis Rheum. 2003; 48: 35–45.Keystone E. C., Kavanaugh A. F., Sharp J. T., Tannenbaum H., Hua Y., Teoh L. S. et al. Radiographic, clinical, and functional outcomes of treatment with Adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy a randomized, placebocontrolled, 52-week trial. Arthritis Rheum. 2004; 50: 1400–1411.Keystone E. C., Kavanaugh A. F., Sharp J. T., Tannenbaum H., Hua Y., Teoh L. S. et al. Radiographic, clinical, and functional outcomes of treatment with Adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy a randomized, placebocontrolled, 52-week trial. Arthritis Rheum. 2004; 50: 1400–1411.Van de Putte L. B., Atkins C., Malaise M., Sany J., Russell A. S., van Riel P. L. et al. Efficacy and safety of Adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004; 63: 508–516.Van de Putte L. B., Atkins C., Malaise M., Sany J., Russell A. S., van Riel P. L. et al. Efficacy and safety of Adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 2004; 63: 508–516.Mease P. J., Gladman D. D., Ritchhn C. T., Ruderman E. M., Steinfeld S. D., Choy E. H. et al. For the ADEPT Study Group Adalimumab for the treatment of patients with moderately to severely active psoratic arthritis results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52: 3279–3289.Mease P. J., Gladman D. D., Ritchhn C. T., Ruderman E. M., Steinfeld S. D., Choy E. H. et al. For the ADEPT Study GroupАлексеева Е. И., Слепцова Т. В., Валиева С. И., Денисова Р. В., Бзарова Т. М., Лисицын А. О., Гудкова Е. Ю., Чомахидзе А. М., Исаева К. Б., Григорьева А. А., Ломакина О. Л. Эффективность и безопасность инфликсимаба у больных ранним ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2009; 8 (4): 42–50.Adalimumab for the treatment of patients with moderately to severely active psoratic arthritis results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52: 3279–3289.Van der Bijl A. E., Breedveld F. C. et al. Adalimumab (humira) is effective in treating patients with rheumatoid arthritis who previously failed infliximab treatment. Ann Rheum Dis. 2005; 64 (Suppl. III): 428.Alekseeva E. I., Sleptsova T. V., Valieva S. I., Denisova R. V., Bzarova T. M., Lisitsyn A. O., Gudkova E. Yu., Chomakhidze A. M., Isaeva K. B., Grigor'eva A. A., Lomakina O. L. Voprosy sovremennoi pediatrii = Current pediatrics. 2009; 8 (4): 42–50.Алексеева Е. И., Григорьева А. А., Денисова Р. В. Причины развития резистентности к ингибиторам ФНО _ и пути ее преодоления. Вопросы современной педиатрии. 2009; 8 (6): 42–47.Van der Bijl A. E., Breedveld F. C. et al. Adalimumab (humira) is effective in treating patients with rheumatoid arthritis who previously failed infliximab treatment. Ann Rheum. Dis. 2005; 64 (Suppl. III): 428.Алексеева Е. И., Лисицын А. О., Карагулян Н. А. Адалимумаб: новые возможности лечения ювенильных артритов. Вопросы современной педиатрии. 2009; 8 (3): 88–94.Alekseeva E. I., Grigor'eva A. A., Denisova R. V. Voprosy sovremennoi pediatrii = Current pediatrics. 2009; 8 (6): 42–47.Lipsky P. E., van der Heijde D. M. F.M., St Clair E. W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000; 343: 1594–1602.Alekseeva E. I., Lisitsyn A. O., Karagulyan N. A. Voprosy sovremennoi pediatrii = Current pediatrics. 2009; 8 (3): 88–94.Feldman M., Brennan P., Maini R. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996; 14: 397–440.Lipsky P. E., van der Heijde D. M. F.M., St Clair E. W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 2000; 343: 1594–1602.Beutler B. The rote of tumor necrosis factor in health and disease. J Rheumatol. 1999; 26 (Suppl. 57): 16–21.Feldman M., Brennan P., Maini R. Role of cytokines in rheumatoid arthritis. Annu Rev. Immunol. 1996; 14: 397–440.Aikawa N. E., De Carvalho J. F., Silva C. A. et al. Immunogenicity of anti-TNF_ agents in autoimmune diseases. Clinic Rev Allerg Immunol. 2010; 38 (2–3): 82–89.Beutler B. The rote of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (Suppl. 57): 16–21.Haibel H., Rudwaleit M., Listing J. et al. Efficacy of Adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008 Jul; 58 (7): 1981–91.Aikawa N. E., De Carvalho J. F., Silva C. A. et al. Immunogenicity of anti-TNF_ agents in autoimmune diseases. Clinic. Rev. Allerg. Immunol. 2010; 38 (2–3): 82–89.Wijbrandts C. A., Klaasen R., Dijkgraaf M. G. еt al. Bone mineral density in rheumatoid arthritis patients 1 year after Adalimumab therapy: arrest of bone loss? Ann Rheum Dis. ARD Online First, published on April 13, 2008 as 10.1136/ard. 2008.091611.Haibel H., Rudwaleit M., Listing J. et al. Efficacy of Adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008 Jul; 58 (7): 1981–1991.Kimel M., Cifaldi M., Chen N., Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol. 2008 Feb; 35 (2): 206–15.Wijbrandts C. A., Klaasen R., Dijkgraaf M. G. еt al. Bone mineral density in rheumatoid arthritis patients 1 year after Adalimumab therapy: arrest of bone loss? Ann Rheum Dis. ARD Online First, published on April 13, 2008 as 10.1136/ard. 2008.091611.Лучихина Е. Л., Каратеев Д. Е., Насонов Е. Л. Первый опыт применения адалимумаба в России: предварительные результаты 24-недельного открытого исследования. Научно-практическая ревматология. 2008; 5: 59–63.Kimel M., Cifaldi M., Chen N., Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol. 2008 Feb; 35 (2): 206–15.Lovell D., Ruperto N., Reiff A., Jung Lawrence K., Higgins G., Kone-Paut I., Jones Olcay Y., McIlraith Melissa J., Andhivarothai N., Kupper H., Giannini Edward H., Peterson T., Martini A. Long-Term Efficacy and Safety of Adalimumab for up to 6 Years in Patients with Juvenile Idiopathic Arthritis. Abstract presented at: 75th Annual scientific meeting of the American College of Rheumatology (ACR) and the 46th Annual meeting of the Association of Rheumatology Health Professionals (ARHP); 11/5/2011 Chicago, IL; USA. 2011. Abstract MIS (7190791).Luchikhina E. L., Karateev D. E., Nasonov E. L. Nauchno-prakticheskaya revmatologiya = Research and practical rheumatology. 2008; 5: 59–63.Schett G., Coates L. C., Zoe R. Ash, Finzel S., Conaghan P. G. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Research & Therapy. 2011; 13 (Suppl. 1): S4.Lovell D., Ruperto N., Reiff A., Jung Lawrence K., Higgins G., Kone-Paut I., Jones Olcay Y., McIlraith Melissa J., Andhivarothai N., Kupper H., Giannini Edward H., Peterson T., Martini A. Long-Term Efficacy and Safety of Adalimumab for up to 6 Years in Patients with Juvenile Idiopathic Arthritis. Abstract presented at: 75th Annual scientific meeting of the American College of Rheumatology (ACR) and the 46th Annual meeting of the Association of Rheumatology Health Professionals (ARHP); 11/5/2011 Chicago, IL; USA. 2011. Abstract MIS (7190791).Vazquez-Сobian L. B., Flynn T., Lehman T. J. A. Adalimumab therapy for childhood uveitis. J Pediatr. 2006; 149: 572–575.Schett G., Coates L. C., Zoe R. Ash, Finzel S., Conaghan P. G. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Research & Therapy. 2011; 13 (Suppl. 1): S4.Tynjala P., Kotaniemi K., Lindahl P. et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anteriorVazquez-Сobian L. B., Flynn T., Lehman T. J. A. Adalimumab therapy for childhood uveitis. J. Pediatr. 2006; 149: 572–575.uveitis. Rheumatology (Oxford). 2008 Mar; 47 (3): 339–44. Epub 2008 Jan 31.Tynjala P., Kotaniemi K., Lindahl P. et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008 Mar; 47 (3): 339–44. Epub 2008 Jan 31.Biester S., Deuter C., Michels H. et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007 Mar; 91 (3): 274–6.Biester S., Deuter C., Michels H. et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007 Mar; 91 (3): 274–276.Heiligenhaus A., Horneff G., Greiner K. et al. Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood. Klin Monatsbl Augenheilkd. 2007 Jun; 224 (6): 526–31.Heiligenhaus A., Horneff G., Greiner K. et al. Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood. Klin. Monatsbl. Augenheilkd. 2007 Jun; 224 (6): 526–31.Алексеева Е. И., Валиева С. И., Денисова Р. В., Бзарова Т. М. Перспективы применения растворимых рецепторов к ФНО _ в терапии ювенильных артритов. Вопросы современной педиатрии. 2008; 7 (5): 51–56.Alekseeva E. I., Valieva S. I., Denisova R. V., Bzarova T. M. Voprosy sovremennoi pediatrii = Current pediatrics. 2008; 7 (5): 51–56.Алексеева Е. И., Митенко Е. В., Валиева С. И., Бзарова Т. М., Денисова Р. В., Исаева К. Б., Слепцова Т. В., Чомахидзе А. М. Эффективность и безопасность терапии адалимумабом у детей с ювенильным идиопатическим артритом и увеитом. Вопросы современной педиатрии. 2012; 11: 82–90.Alekseeva E.I., Mitenko E.V., Valieva S.I., Bzarova T.M., Denisova R.V., Isaeva K.B., Sleptsova T.V., Chomakhidze A.M. Voprosy sovremennoi pediatrii = Current pediatrics. 2012; 11: 82–90.Намазова-Баранова Л.С. Научные исследования и инфраструктура платформы «Педиатрия». Педиатрическая фармакология. 2012; 9 (4): 15–24.Namazova-Baranova L.S. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9 (4): 15–24.

The authors declare that there are no conflicts of interest present.